By Fineline Cube 
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced that it has received clearance from the US Food and Drug Administration (FDA) for a clinical trial application of its antibody-drug conjugate (ADC) candidate SKB518. This approval allows the company to evaluate the drug in patients with advanced solid tumors.
SKB518: Development and Technology
SKB518 was developed using Kelun-Biotech’s proprietary OptiDC platform technology. Preclinical studies have shown that the drug exhibits a favorable efficacy and safety profile. The FDA clearance follows the initiation of a Phase I clinical study in China in June of the previous year, further advancing the drug’s clinical development.-Fineline Info & Tech